{"id":"apatinib-combined-with-docetaxel","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"},{"rate":"5-20%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL3186534","moleculeType":"Small molecule","molecularWeight":"397.48"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Apatinib works by selectively inhibiting the tyrosine kinase activity of VEGFR2, which is involved in the regulation of angiogenesis. This leads to the inhibition of tumor growth and metastasis. Apatinib has been shown to have anti-tumor activity in various types of cancer.","oneSentence":"Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:43.436Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic gastric cancer"},{"name":"Metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06346392","phase":"PHASE3","title":"AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-04","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":572},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT05156970","phase":"PHASE2","title":"Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2021-06-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":81},{"nctId":"NCT06769425","phase":"PHASE1","title":"HS-10502 Combination Treatment in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-05-07","conditions":"Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer","enrollment":157},{"nctId":"NCT06745193","phase":"PHASE2","title":"A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2025-02-01","conditions":"Advanced Esophageal Carcinoma","enrollment":63},{"nctId":"NCT05549466","phase":"PHASE2","title":"Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-10-08","conditions":"Nasopharyngeal Carcinoma","enrollment":84},{"nctId":"NCT05649163","phase":"","title":"Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy","status":"UNKNOWN","sponsor":"Shen Lin","startDate":"2023-01","conditions":"HER2, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Adenocarcinoma","enrollment":306},{"nctId":"NCT04878107","phase":"PHASE2","title":"SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy","status":"UNKNOWN","sponsor":"Wuhan University","startDate":"2022-03-15","conditions":"Non-Small Cell Lung Cancer","enrollment":88},{"nctId":"NCT03787251","phase":"PHASE2","title":"A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib","status":"WITHDRAWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2019-01-01","conditions":"Esophageal Neoplasms","enrollment":""},{"nctId":"NCT03917966","phase":"PHASE2","title":"The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2020-04-07","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":80},{"nctId":"NCT03243838","phase":"PHASE2","title":"Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2018-08-01","conditions":"Triple-Negative Breast Cancer","enrollment":31},{"nctId":"NCT05029453","phase":"PHASE4","title":"Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-08-26","conditions":"Gastric Cancer, Randomized Controlled Study","enrollment":60},{"nctId":"NCT03580395","phase":"PHASE2, PHASE3","title":"Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer","status":"UNKNOWN","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2017-06-01","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT04781686","phase":"PHASE2","title":"Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"Zhou Fuxiang","startDate":"2021-05-14","conditions":"Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma","enrollment":35},{"nctId":"NCT03154983","phase":"PHASE2","title":"The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"Zhou Fuxiang","startDate":"2017-05-20","conditions":"Metastatic Gastric Cancer","enrollment":48},{"nctId":"NCT03547804","phase":"PHASE2","title":"A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer","status":"COMPLETED","sponsor":"The First Hospital of Jilin University","startDate":"2018-05-31","conditions":"Small-cell Lung Cancer","enrollment":31},{"nctId":"NCT03758677","phase":"PHASE2","title":"Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2020-08-01","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT03349827","phase":"NA","title":"HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer","status":"TERMINATED","sponsor":"Wuhan University","startDate":"2018-01-05","conditions":"Peritoneal Metastases From Gastric Cancer","enrollment":20},{"nctId":"NCT03671265","phase":"NA","title":"Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-09-17","conditions":"Esophageal Cancer","enrollment":20},{"nctId":"NCT03416231","phase":"PHASE2","title":"Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Affiliated Hospital of North Sichuan Medical College","startDate":"2016-11-30","conditions":"NSCLC","enrollment":20},{"nctId":"NCT03411967","phase":"PHASE2","title":"Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC","status":"UNKNOWN","sponsor":"Zigong No.1 Peoples Hospital","startDate":"2018-02-01","conditions":"Lung Cancer","enrollment":20},{"nctId":"NCT03393507","phase":"PHASE2","title":"A Study of Apatinib Treatment in for Advanced Ovarian Cancer","status":"UNKNOWN","sponsor":"The People's Hospital of Leshan","startDate":"2017-08-01","conditions":"Ovarian Cancer, Chemotherapeutic Toxicity","enrollment":34},{"nctId":"NCT03193424","phase":"PHASE2","title":"Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2016-10","conditions":"Advanced Esophageal Squamous Carcinoma","enrollment":120},{"nctId":"NCT03071042","phase":"PHASE1","title":"A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2015-10","conditions":"Metastatic Gastric Adenocarcinoma","enrollment":12},{"nctId":"NCT02852798","phase":"","title":"Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC","status":"UNKNOWN","sponsor":"Jiangsu ShengDiYa Medicine Co., Ltd.","startDate":"2016-08","conditions":"Nonsquamous Nonsmall Cell Neoplasm of Lung","enrollment":60},{"nctId":"NCT02691871","phase":"PHASE1","title":"Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2016-02","conditions":"Lung Adenocarcinoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AITAN"],"phase":"phase_2","status":"active","brandName":"Apatinib Combined With Docetaxel","genericName":"Apatinib Combined With Docetaxel","companyName":"Jiangsu ShengDiYa Medicine Co., Ltd.","companyId":"jiangsu-shengdiya-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis. Used for Metastatic gastric cancer, Metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}